Spots Global Cancer Trial Database for Evaluating Patient Participation in Phase I Clinical Trials

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Evaluating Patient Participation in Phase I Clinical Trials

Official Title: Survey Of Patient's Motivations, Perceptions, And Expectations In Phase I Clinical Trials

Study ID: NCT00043030

Conditions

Psychosocial Effects of Cancer and Its Treatment

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

psychosocial assessment and care

Study Description

Brief Summary: RATIONALE: Understanding why patients participate in a phase I clinical trial may help doctors plan better treatment for cancer. PURPOSE: This clinical trial is studying to determine the reasons for participation, perceptions, and expectations of patients receiving treatment for cancer in phase I clinical trials.

Detailed Description: OBJECTIVES: * Describe the motivations, perceptions, and expectations of patients enrolled in a phase I clinical trial. * Assess the influence of age, education, and gender upon the perception of these patients. * Compare the difference in perceptions, motivations, and expectations of patients who have previously participated in a phase I clinical trial vs those who have not. * Determine whether patients' perceptions, motivations, and expectations change while enrolled in a phase I clinical trial. * Validate an interviewer-administered tool measuring the perceptions, motivations, and expectations of these patients. * Assess patients' perception of the information they were given while enrolled in a phase I clinical trial. OUTLINE: Patients are interviewed over the phone to evaluate their perceptions, motivations, and expectations of phase I clinical trials. Patients complete a questionnaire comprising 24 questions over 30-45 minutes. Interviews are conducted within 1 week after enrolling in a phase I clinical trial (prior to the first dose of study agent) and then again 2 months later (or at the time the patient stops treatment). The first 10 patients enrolled complete an additional 6 questions over 15 minutes during the first interview to validate the questionnaire, but do not complete a second interview. PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study within 1 year.